Matinas Biopharma (MTNB) Competitors $1.90 +0.02 (+1.06%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.08 (-4.21%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. LIMN, JSPR, ATHE, DYAI, XLO, PLUR, XFOR, GBIO, MRSN, and SNTIShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Liminatus Pharma (LIMN), Jasper Therapeutics (JSPR), Alterity Therapeutics (ATHE), Dyadic International (DYAI), Xilio Therapeutics (XLO), Pluri (PLUR), X4 Pharmaceuticals (XFOR), Generation Bio (GBIO), Mersana Therapeutics (MRSN), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors Liminatus Pharma Jasper Therapeutics Alterity Therapeutics Dyadic International Xilio Therapeutics Pluri X4 Pharmaceuticals Generation Bio Mersana Therapeutics Senti Biosciences Matinas Biopharma (NYSE:MTNB) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends. Do institutionals & insiders hold more shares of MTNB or LIMN? 11.8% of Matinas Biopharma shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate MTNB or LIMN? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to MTNB or LIMN? In the previous week, Matinas Biopharma and Matinas Biopharma both had 1 articles in the media. Liminatus Pharma's average media sentiment score of 1.91 beat Matinas Biopharma's score of 0.15 indicating that Liminatus Pharma is being referred to more favorably in the news media. Company Overall Sentiment Matinas Biopharma Neutral Liminatus Pharma Very Positive Which has stronger valuation & earnings, MTNB or LIMN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas BiopharmaN/AN/A-$22.94M-$3.89-0.49Liminatus PharmaN/AN/AN/AN/AN/A Is MTNB or LIMN more profitable? Liminatus Pharma's return on equity of 0.00% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Liminatus Pharma N/A N/A N/A SummaryMatinas Biopharma and Liminatus Pharma tied by winning 3 of the 6 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$9.67M$861.64M$5.66B$21.54BDividend YieldN/A4.84%5.75%3.52%P/E Ratio-0.391.2175.7529.48Price / SalesN/A26.21560.9560.08Price / CashN/A17.6537.6024.33Price / Book0.436.4612.414.57Net Income-$22.94M-$5.42M$3.29B$1.00B7 Day Performance8.57%-0.26%1.26%-0.20%1 Month Performance-9.52%5.21%3.84%2.42%1 Year PerformanceN/A25.78%61.01%13.12% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas Biopharma0.1617 of 5 stars$1.90+1.1%N/AN/A$9.67MN/A-0.3930Gap DownLIMNLiminatus PharmaN/A$1.58+10.7%N/AN/A$41.18MN/A0.00N/APositive NewsHigh Trading VolumeJSPRJasper Therapeutics3.7861 of 5 stars$2.51-1.2%$25.63+920.9%-87.2%$40.79MN/A-0.4220News CoverageATHEAlterity Therapeutics2.8387 of 5 stars$4.51+1.8%$12.00+166.1%+228.0%$40.00MN/A0.0010DYAIDyadic International2.6638 of 5 stars$1.10+6.3%$6.00+447.9%+3.5%$39.63M$3.49M-5.767XLOXilio Therapeutics2.6435 of 5 stars$0.76-0.3%$3.00+293.2%+0.9%$39.55M$6.34M-1.0070Positive NewsPLURPluri3.0396 of 5 stars$4.77+1.2%$12.00+151.8%-23.3%$38.88M$1.34M-0.92150Positive NewsXFORX4 Pharmaceuticals4.6311 of 5 stars$3.38flat$34.17+910.8%-82.5%$38.57M$2.56M-0.2380Positive NewsGBIOGeneration Bio4.0649 of 5 stars$5.62-3.0%$10.67+90.0%-77.5%$38.18M$19.89M-0.52150Positive NewsMRSNMersana Therapeutics4.3063 of 5 stars$7.48+1.7%$56.60+656.9%-84.1%$37.23M$40.50M-0.51150Positive NewsSNTISenti Biosciences3.2561 of 5 stars$1.39-0.4%$8.50+513.7%-39.1%$36.26M$2.56M-0.154 Related Companies and Tools Related Companies LIMN Alternatives JSPR Alternatives ATHE Alternatives DYAI Alternatives XLO Alternatives PLUR Alternatives XFOR Alternatives GBIO Alternatives MRSN Alternatives SNTI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTNB Stock Alerts